Guangdong Association of Clinical Trials
🇨🇳China
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 200
- Registration Number
- NCT04768075
Efficacy and Safety of Camrelizumab in Real-World Study
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 450
- Registration Number
- NCT04631146
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 272
- Registration Number
- NCT04575415
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 50
- Registration Number
- NCT04339829
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 1000
- Registration Number
- NCT04306042
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 100
- Registration Number
- NCT04286841
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 20
- Registration Number
- NCT04252365
A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 48
- Registration Number
- NCT04015778
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 120
- Registration Number
- NCT04007835
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 106
- Registration Number
- NCT03768037
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath